SCHEMBL4720873

SCHEMBL4720873

CCCCN(CCCC)N1CCOCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
POLB P06746 3/20 0.37
HTT P42858 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 4/20 0.36
MAPK1 P28482 2/20 0.36
SIGMAR1 Q99720 2/20 0.36
CYP1A2 P05177 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
HTR2A P28223 1/20 0.36
SCN1A P35498 1/20 0.36
HTR2B P41595 1/20 0.36
KCNH2 Q12809 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
USP2 O75604 1/20 0.35
HPGD P15428 2/20 0.33
MLYCD O95822 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4721519 0.96 LMNA (0.35) LMNAPOLBHTTSMN1; SMN2ALDH1A1
SCHEMBL4719946 0.94 POLB (0.36) LMNAPOLBHTTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL28309112 0.90 DNM1 (0.40) LMNAPOLBHTTSMN1; SMN2ALDH1A1
Bromide SCHEMBL28309885 0.90 DNM1 (0.40) LMNAPOLBHTTSMN1; SMN2ALDH1A1
Bromide SCHEMBL28875153 0.90 DNM1 (0.40) LMNAPOLBHTTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL28309047 0.90 DNM1 (0.40) LMNAPOLBHTTSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL28309131 0.90 DNM1 (0.40) LMNAPOLBHTTSMN1; SMN2ALDH1A1
SCHEMBL11127851 0.88 LMNA (0.32) LMNAPOLBHTTSMN1; SMN2ALDH1A1
SCHEMBL4723949 0.86 SMN1; SMN2 (0.32) LMNAPOLBHTTSMN1; SMN2ALDH1A1
SCHEMBL4723915 0.81 LMNA (0.40) LMNAPOLBHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
US-5424402-A Non-destructive method for radiolabelling biomolecules by halogenation BOARD OF TRUSTEES OF THE UNIVERSITY OF KENTUCKY (US) 1995-06-13 US disclosed
US-4689354-A STYRENE GRAFTED POLYESTERETHER POLYOLS, CHAIN TRANSFERAGENTS, UNSATURATION BASF CORPORATION (US) 1987-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 LMNA 2692/4885POLB 2602/4885HTT 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.